These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 28142109)

  • 41. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
    Tarantino MD; Fogarty PF; Shah P; Brainsky A
    Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
    [TBL] [Abstract][Full Text] [Related]  

  • 42. European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia.
    Barlassina A; González-López TJ; Cooper N; Zaja F
    Platelets; 2023 Dec; 34(1):2170999. PubMed ID: 36803535
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytomegalovirus-associated thrombocytopenia treated with thrombopoietin receptor agonist.
    Simpson JD; Matthews GV; Brighton TA; Joseph JE
    Intern Med J; 2016 Sep; 46(9):1096-9. PubMed ID: 27633469
    [TBL] [Abstract][Full Text] [Related]  

  • 44. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.
    D'Arena G; Guariglia R; Mansueto G; Martorelli MC; Pietrantuono G; Villani O; Lerose R; Musto P
    Blood; 2013 Feb; 121(7):1240-2. PubMed ID: 23411736
    [No Abstract]   [Full Text] [Related]  

  • 45. Moving towards a new era in the management of chronic immune thrombocytopenia.
    Wadenvik H; Olsson B
    Ann Hematol; 2010 Jul; 89 Suppl 1():87-93. PubMed ID: 20339846
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center.
    Suntsova EV; Maschan AA; Baydildina DD; Kalinina II; Petrova UN; Pshonkin AV; Novichkova GA
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27704. PubMed ID: 30854783
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.
    Tomiyama Y; Miyakawa Y; Okamoto S; Katsutani S; Kimura A; Okoshi Y; Ninomiya H; Kosugi H; Nomura S; Ozaki K; Ikeda Y; Hattori T; Katsura K; Kanakura Y
    J Thromb Haemost; 2012 May; 10(5):799-806. PubMed ID: 22409309
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Severe immune thrombocytopenia in pregnancy treated with Eltrombopag - A case report.
    Ferreira IJMCF; Sousa F; Vasco EM; Areia ALFA; Moura JPAS; Carda J; Ribeiro L
    J Gynecol Obstet Hum Reprod; 2018 Oct; 47(8):405-408. PubMed ID: 29981476
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A study of immunocyte subsets and serum cytokine profiles before and after immunal suppression treatment in patients with immune thrombocytopenia].
    Li W; Wang X; Li J; Liu M; Feng J
    Zhonghua Nei Ke Za Zhi; 2016 Feb; 55(2):111-5. PubMed ID: 26875579
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.
    Bento L; Bastida JM; García-Cadenas I; García-Torres E; Rivera D; Bosch-Vilaseca A; De Miguel C; Martínez-Muñoz ME; Fernández-Avilés F; Roldán E; Chinea A; Yáñez L; Zudaire T; Vaz CP; Espigado I; López J; Valcárcel D; Duarte R; Cabrera R; Herrera C; González-Porras JR; Gutiérrez A; Solano C; Sampol A;
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1825-1831. PubMed ID: 31152794
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia].
    Horikoshi A; Tsukuda J; Abe R; Fujiwara N; Ito E; Takaku T
    Rinsho Ketsueki; 2016 May; 57(5):638-41. PubMed ID: 27263792
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia.
    González-López TJ; Sánchez-González B; Pascual C; Arefi M; de Cabo E; Alonso A; Martín-Salces M; Jiménez-Bárcenas R; Calbacho M; Galan P; Barez A; González-Porras JR
    Platelets; 2015; 26(1):83-6. PubMed ID: 24499036
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.
    Depré F; Aboud N; Mayer B; Salama A
    Blood Transfus; 2018 May; 16(3):307-312. PubMed ID: 28151387
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Involvement of levels of Toll like receptor-4 in monocytes, CD4+ T-lymphocyte subsets, and cytokines in patients with immune thrombocytopenic purpura.
    Liu H; Ouyang X; Li Y; Zeng H; Wang X; Xie S; Nie D; Xiao J; Wei J; Wu Y; Yin S; Ma L
    Thromb Res; 2013 Aug; 132(2):196-201. PubMed ID: 23830211
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The cytokines (IFN-gamma, IL-2, IL-4, IL-10, IL-17) and Treg cytokine (TGF-beta1) levels in adults with immune thrombocytopenia.
    Ma L; Liang Y; Fang M; Guan Y; Si Y; Jiang F; Wang F
    Pharmazie; 2014 Sep; 69(9):694-7. PubMed ID: 25272942
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia.
    Nazy I; Kelton JG; Moore JC; Clare R; Horsewood P; Smith JW; Ivetic N; D'Souza V; Li N; Arnold DM
    Br J Haematol; 2018 Apr; 181(2):234-241. PubMed ID: 29532903
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
    González-López TJ; Pascual C; Álvarez-Román MT; Fernández-Fuertes F; Sánchez-González B; Caparrós I; Jarque I; Mingot-Castellano ME; Hernández-Rivas JA; Martín-Salces M; Solán L; Beneit P; Jiménez R; Bernat S; Andrade MM; Cortés M; Cortti MJ; Pérez-Crespo S; Gómez-Núñez M; Olivera PE; Pérez-Rus G; Martínez-Robles V; Alonso R; Fernández-Rodríguez A; Arratibel MC; Perera M; Fernández-Miñano C; Fuertes-Palacio MA; Vázquez-Paganini JA; Gutierrez-Jomarrón I; Valcarce I; de Cabo E; Sainz A; Fisac R; Aguilar C; Paz Martínez-Badas M; Peñarrubia MJ; Calbacho M; de Cos C; González-Silva M; Coria E; Alonso A; Casaus A; Luaña A; Galán P; Fernández-Canal C; Garcia-Frade J; González-Porras JR
    Am J Hematol; 2015 Mar; 90(3):E40-3. PubMed ID: 25400215
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
    Kuter DJ
    Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Age and Bone Marrow Cellularity are Associated with Response to Eltrombopag in Japanese Adult Immune Thrombocytopenia Patients: A Retrospective Single-Center Study.
    Uto Y; Fujiwara S; Arai N; Kawaguchi Y; Kabasawa N; Tsukamoto H; Ariizumi H; Hattori N; Saito B; Yanagisawa K; Harada H; Mori H; Shiozawa E; Nakamaki T
    Rinsho Byori; 2015 May; 63(5):548-56. PubMed ID: 26524893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.